drugset

Drugs / Brilaroxazine

Follow last change Feb 2025 re-read 2 minutes ago

Brilaroxazine

also known as BRILAROXAZINE HYDROCHLORIDE · RP-5063 HYDROCHLORIDE · RP5063

Developed for: schizoaffective disorder · schizophrenia
Investigated by: Reviva Pharmaceuticals

Trials 1 · a red edge is where a trial was stopped

today NCT01490086 · Ph 2

2012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT01490086	Dec 2011 → Mar 2013	schizoaffective disorder, schizophrenia	Reviva Pharmaceuticals	Completed	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 3	NCT05184335 Comparator	Jan 2022 → Feb 2025 overdue	schizophrenia	Reviva Pharmaceuticals	Recruiting	No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	Brilaroxazine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05184335 ↗
Known as	BRILAROXAZINE HYDROCHLORIDE	ChEMBL registry synonym — accepted as the source's own label CHEMBL5095172 ↗
Known as	RP-5063 HYDROCHLORIDE	ChEMBL registry synonym — accepted as the source's own label CHEMBL5095172 ↗
Known as	RP5063	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01490086 ↗
Modality	Small molecule	— CHEMBL5095172 ↗